PCI Pharma Services (PRIVATE.PCIPHARMA)

Overall impact
C (49)

Commentary

PCI Pharma Services is an average overall performer. With a 'C' rating of 48.7 for overall impact (38th percentile compared to all companies), PCI Pharma Services ranks 556th out of 585 industry peers, behind Grifols, Biogen, Ionis Pharmaceuticals and 552 others, and ahead of Jazz Pharmaceuticals, Fulcrum Therapeutics, SAGE Therapeutics and 26 others. On top material causes for PCI Pharma Services's industry (Pharmaceuticals & Biotech), PCI Pharma Services performs well in Disease Eradication (83.5 score) and Technology Innovation (95.0) and performs poorly in Decent, Safe Work Opportunities (26.8 score), Improved Mental Health (23.1), Reduced Green House Gas Emissions (33.6) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.PCIPHARMA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2012
Employees
7,000
Sector
Health Care
Industry
Life Sciences Tools & Services
Sub-industry
Life Sciences Tools & Services
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Pennsylvania, United States
Share classes
PRIVATE.PCIPHARMA
Description
Provider of integrated pharmaceutical development services to healthcare companies. The company provides pharmaceutical services like analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging as well as QP services. Additionally, they offer supply chain management, storage, and distribution to the healthcare industry.
Material causes
Ethos considers the following causes material for PCI Pharma Services, based on its industry sub-industry Life Sciences Tools & Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.